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Mutation of IGFBP7 Causes Upregulation of BRAF/MEK/ERK
Pathway and Familial Retinal Arterial Macroaneurysms
Leen Abu-Safieh,1,10 Emad B. Abboud,2,10 Hisham Alkuraya,1,2,10 Hanan Shamseldin,1 Shamsa Al-Enzi,1
Lama Al-Abdi,1 Mais Hashem,1 Dilek Colak,3 Abdullah Jarallah,4 Hala Ahmad,5 Steve Bobis,5
Georges Nemer,6 Fadi Bitar,7 and Fowzan S. Alkuraya1,8,9,*
Insulin-like growth factor binding proteins (IGFBPs) play important physiological functions through the modulation of IGF signaling as
well as IGF-independentmechanisms. Despite the established role of IGFs in development, a similar role for the seven known IGFBPs has
not been established in humans. Here, we show that an autosomal-recessive syndrome that consists of progressive retinal arterial macro-
aneurysms and supravalvular pulmonic stenosis is caused by mutation of IGFBP7. Consistent with the recently established inhibitory
role of IGFBP7 on BRAF signaling, the BRAF/MEK/ERK pathway is upregulated in these patients, which may explain why the cardiac
phenotype overlaps with other disorders characterized by germline mutations in this pathway. The retinal phenotype appears to be
mediated by a role in vascular endothelium, where IGFBP7 is highly expressed.Insulin-like growth factors IGF1 (MIM 147440) and IGF2
(MIM 147470) are signaling polypeptides that are involved
in a wide array of physiological functions both embryolog-
ically and postnatally by promoting growth and inhibiting
apoptosis.1 Their bioavailability to the receptors that
mediate their signaling is highly regulated by their binding
to a family of binding proteins (IGFBPs), seven of which
have been described to date in humans.1 Although IGFBPs
were initially investigated in connection to IGF signaling,
there is accumulating evidence that they have physiolog-
ical roles that are independent of their classical role as
binding partners of IGFs. For example, IGFBP1 (MIM
146730) is known to counteract apoptosis in hepatocytes
by binding to BAK, which impairs formation of the proa-
poptotic p53/BAK complex,2 IGFBP3 (MIM 146732) upre-
gulates STAT1 to promote apoptosis in chondrocytes in
an IGF-independent manner,3 and IGFBP4 (MIM 146733)
directly binds to Fzd8 (MIM 606146) and LRP6 (MIM
603507), making them less available to their ligand Wnt3
and thus creating an inhibitory effect on the canonical
Wnt signaling.4
There is evidence to suggest a potential developmental
role for IGFBPs. IGFBP1, for example, has been shown to
regulate hypoxia-induced fetal growth retardation, IGFBP4
is a cardiogenic factor, and Igfbp5 (MIM 146734) overex-
pression confers increased neonatal mortality and retarded
growth and muscle development.4–6 However, and in con-
trast to the demonstrated developmental role of the Igfs in
knockout mice, a similar role for any of the IGFBPs has not
been easy to establish, in part because compensation and
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out.5,7 Therefore, study of IGFBPs in humans has largely
been limited to their role in cellular metabolism, both
under physiological conditions and in pathologies, mostly
malignancies.8–10
One of the current authors has previously described a
retinal vascular phenotype in which several patients had
a strikingly similar appearance of ‘‘beading’’ along the
major retinal arterial trunks, with the formation of macro-
aneurysms. The mode of inheritance could not be estab-
lished from the three original families, but the familial
occurrence prompted the designation of familial retinal
artery macroaneurysms, or FRAM.11 Here, we expand the
clinical definition of this syndrome and show that it is
an autosomal-recessive condition caused by a founder
mutation in IGFBP7 (MIM 602867).
Patients with FRAM and their relatives were recruited
under an IRB-approved protocol (of the King Faisal Spe-
cialist Hospital and Research Center and the King Khaled
Eye Specialist Hospital) with written informed consent.
Patients had a thorough dysmorphologic, ophthalmologic,
and cardiologic evaluation. Eight Saudi families, for a total
of 22 patients, were identified in the course of this study;
patient ages ranged from 4 to 37 years. The eight pedigrees
were highly suggestive of an autosomal-recessive mode of
inheritance, and pseudodomiant inheritance was observed
in one pedigree (Figure 1A). The classical presentation of
macroaneurysms involving the retinal artery was seen in
all patients, the youngest being 4 years of age, and some
older patients have evidence of beading that extends
well into the retinal periphery but at decreasing severityer, Riyadh 11211, Saudi Arabia; 2Vitreoretinal Division, King Khaled Eye
Epidemiology and Computing, King Faisal Specialist Hospital and Research
alid University Hospital and College of Medicine, Riyadh 11462, Saudi Ara-
Research Center, Riyadh 11211, Saudi Arabia; 6Department of Biochemistry
non; 7Department of Pediatrics, American University of Beirut, Beirut 1107
, Alfaisal University, Riyadh 11533, Saudi Arabia; 9Department of Pediatrics,
i Arabia
Genetics. All rights reserved.
an Journal of Human Genetics 89, 313–319, August 12, 2011 313
Figure 1. FRAM Is an Autosomal-Recessive Syndrome Defined by Retinal and Cardiac Phenotypes
(A) Pedigrees of eight Saudi families with FRAM. Note the positive consanguinity in all families and the pseudodominant inheritance in
family 004.
(B) Representative fundus photo showing marked beading of the retinal artery on the optic nerve and along the major trunks. Many
macroaneursyms are seen, either that are actively leaking with hard yellow exudate or that are cicatricial.
(C) A short-axis view of the echocardiography, showing color turbulence with a Doppler pulse wave, giving a gradient of 20mmHg at the
supravalvular level of the pulmonary outflow tract.
(D) Clinical photograph of a patient with FRAM; note the lack of facial dysmorphism.(Figure 1B). In addition, a unique phenotype of supravalv-
ular pulmonic stenosis was seen in all patients who under-
went echocardiography (nine declined examination) and
often required surgical correction due to its adverse hemo-
dynamic consequences (Figure 1C). No obvious dysmor-
phic features or evidence of other system involvement
was noted (Figure 1D). Two patients died in the course of
the study as a result of complications of their pulmonic
stenosis and suspected congestive hepatopathy.
Whole-blood DNA was extracted, followed by genotyp-
ing on Affy 250StyI SNP Chip per the manufacturer’s
protocol (Affymetrix, Santa Clara, CA, USA). A homozy-
gosity scan was performed with Genotyping Console, and
linkage analysis was performed on easyLINKAGE via an
autosomal-recessive model with 100% penetrance as previ-
ously described.12 Eachof the eight families showeda runof
homozygosity (ROH) on chromosome 4. Collectively, a
LOD score of 11.4 was obtained for a locus delimited by
SNPs rs6833480 and rs10017149 (~5.1 Mb) (Figure S1).
Analysis with microsatellites and additional SNPs further314 The American Journal of Human Genetics 89, 313–319, August 1refined the region to a smaller locus (~4.7Mb) flanked by
rs76451666 and D4S398; this locus contained five anno-
tated genes and one hypothetical gene (Figure 2). Our anal-
ysis of the genes in theminimal linkage interval (n¼6) only
revealed the presence of previously reported SNPs (TT
rs115656299 and TT rs10866440 in REST [MIM 600571];
and AA rs1718878 and CC rs1718866 in POLR2B [MIM
180661]) except in IGFBP7, which was found to harbor
a splicing variant c.830-1G>A (NM_001553.1) (Figure 2).
This consensus acceptor-site mutation segregated perfectly
with the disease in all families. Microsatellite analysis and
analysis of additional SNPs obtained when the samples
were runon the denser Axiomarray (Affymetrix) confirmed
the presence of a common haplotype that is bordered by
D4S1592 and rs12501656 and spans 96 SNPs over a
351kb genomic interval (Table S1). Screening of 300 Saudi
controls (600 chromosomes) revealed the presence of
only one heterozygous carrier, whose genotypic analysis
confirmed that he harbors this mutation on the same
disease haplotype, making him a likely carrier.2, 2011
Figure 2. FRAM Is Caused by a Founder Splicing Mutation in IGFBP7
(A) Linkage analysis showing a very high LOD score of 11.4 on chromosome 4 on the first five families combined. Dotted lines emerging
from the highest peak demarcate the critical linkage interval, which is further narrowed by the heterozygosity observed for flanking
markers rs76451666 and D4S398, which only encompasses six genes, including IGFBP7 (shown in red with sequence chromatogram
indicating the site of the G>A transition by a red asterisk). The common founder haplotype is flanked by D4S1592 and rs12501656.
(B) RT-PCR and 30RACE, respectively, confirm the skipping of exon 5 and the lack of polyadenylation of the resulting aberrant transcript.
(C) Immunoblot analysis shows more intense (130%) IGFBP7 in patient lymphoblasts (family F005 II-1, II-2 and II-4, from left to right)
than in the control.RT-PCR with a reverse primer on exon 5 confirmed that
this mutation fully abolishes the normal splice acceptor
site in that no product could be seen in patients (Figure 2).
In order to investigate the full extent of aberrant splicing,
we performed a 30RACE experiment, which failed to
recover any IGFBP7-specific transcript from the patient,
whereas the expected transcript was readily identified in
the control (Figure 2). This is most likely explained byThe America lack of polyadenylation signal from exon 4, which re-
sulted in a lack of poly-A tail addition to the aberrant tran-
script that lacks exon 5. To circumvent this limitation, we
performed RT-PCR by using a forward primer in exon 1 and
a reverse primer in intron 4 (data not shown). The result
indicated that in the patient, but not in the control, tran-
scription continues into intron 4 and introduces a stop
codon 7 bp downstream of the exon 4/intron 4 junction.an Journal of Human Genetics 89, 313–319, August 12, 2011 315
Figure 3. Igfbp7 Is Expressed in the Retinal Vasculature
(A) WISH on E12 mouse embryos showing expression domains in
the eye (lens and surrounding retina); a sense probe is shown as
a negative control.
(B) A flat-mount retina is used for immunohistochemistry with
Igfbp7 antibody and isolectin-IB4 stain (latter is a marker for blood
vessels). Note the positive staining in the superficial scans (1–3),
which include major smooth-muscle-invested retinal vasculature,
but the largely negative staining in the deeper scans (4–6), where
smaller capillaries are more common. This is further confirmed in
sections where specific Igfbp7 is shown surrounding larger vessels
(7–9, inset). Staining with only secondary antibody shows no
Igfbp7 staining (10–12).This aberrant transcript, therefore, predicts loss of the last
five amino acids at the C terminus of an otherwise 282 aa
IGFPB7 protein (29.13 kD) and their replacement by two
novel amino acids for a total size of 279 aa (28.86 kD). At
the protein level, immunoblot analysis with an antibody
against the domains encoded by exons 3 and 4 of IGFBP7
consistently revealed a more intense band in patients than
in controls (Figure 2). The reason for this increase is un-
clear, but one possible explanation is defective secretion
of the mutant protein. Another possibility is that the small
truncation in the C terminus of the mutant protein re-
moves a negative-feedback effect that is normally exerted
so that the level of IGFBP7 is kept in the normal range.
The above experimental evidence that no normal
IGFBP7 transcript is made in blood cells from FRAM
patients who are homozygous for this mutation makes it
likely that the mutation we report is pathogenic. In addi-
tion, this mutation is not observed in any of the public
SNP databases, including that of the 1000 Genomes
Project. Our finding of a single heterozygous individual
out of 300 Saudi controls should not be viewed as evidence
that this is a Saudi-specific benign variant because haplo-
type analysis of this individual confirmed that he harbors
the same disease haplotype in the heterozygous state,
making him a likely carrier of a disease mutation.
In order to examine IGFBP7 expression and its relevance
to the phenotype in FRAM patients, we performed whole-
mount in situ hybridization (WISH) experiments by using
riboprobes for Igfbp7 onmouse embryos with InsituPro VSi
(Intavis, Koeln, German) according the manufacturer’s
protocol. This showed that Igfbp7 is indeed expressed in
the eye (both lens and retina) (Figure 3). Although these
results support a restricted pattern of expression, they do
not provide a robust link to the retinal phenotype seen
in FRAM patients because the murine retinal vasculature
develops postnatally. Indeed, longitudinal follow up of
the retinal phenotype in FRAM suggested that it is only
discernible at 4 years of age. Therefore, we resorted to im-
munohistochemistry analysis on retinal flat mounts and
sections prepared from adult mice and with rat anti-mouse
Igfbp7 antibody (R&D, catalog number MAB21201),
which revealed an interesting expression pattern in the
retinal vasculature, where Igfbp7 is localized to the larger,
smooth-muscle-invested vasculature but not in the smaller
capillaries. Localization surrounding the vessels is compat-
ible with extracellular secretion of Igfbp7 (Figure 3).
The overlapping cardiac features of FRAM (supravalvular
pulmonic stenosis) with that of Noonan spectrum disor-
ders (mostly valvular pulmonic stenosis, but supravalvular
location has also been observed13) led us to investigate
a potential mechanistic link. Indeed, global gene-expres-
sion profiling of patient lymphoblasts (performed in tripli-
cates with Affymetrix’s GeneChip Human Genome U133
Plus 2.0 Arrays) was consistent with upregulation of
BRAF and downstream targets of the Ras/MAPK pathway
(significantly modulated genes were defined as those
with an absolute n-fold change of n > 2 and adjusted316 The American Journal of Human Genetics 89, 313–319, August 1p value < 0.05, and we used Benjamini-Hochberg step-up
procedure to cap the false-discovery rate at 5%).14 To verify
that the increased level of the components of the Ras/
MAPK pathway is associated with increased signaling,
which is characteristic of Noonan-spectrum disorders
(Rasopathies), we show that the active phosphorylated
form of EPHB2 (most commonly known as ERK [MIM
600997]) is markedly increased, whereas the level of total
ERK remains unaltered (Figure 4; see also Figure S2).
In 2002, Dhindsa and Abboud described an apparently
novel entity that they referred to as familial retinal artery
macroaneurysm (FRAM) in three unrelated families (fami-
lies 003 and 004 in this study and one that was lost for
follow-up).11 The condition was most unusual in that
aneurysms specifically of the retinal artery were seen at
a very young age. No conclusion was made about the2, 2011
Figure 4. FRAM Is Characterized by Increased
Signaling of the BRAF/MEK/ERK Pathway
(A) IPA analysis led to the generation of a gene-
interaction network of genes differentially ex-
pressed in patients. Nodes represent genes, the
shape of the node represents the functional class
of the gene product, and the edges indicate the
biological relationship between the nodes. Green
indicates downregulation, and red indicates up-
regulation in patients compared to controls.
The color intensity is correlated with the n-fold
change.
(B) Upregulation of BRAF and p-ERK is confirmed
at the protein level in patient lymphoblasts
(family F005 II-1, II-2, and II-4, from left to right)
compared to those of two controls. BRAF shows
100% increased intensity, and p-ERK shows
170% increased intensity in patients compared
to two controls.mode of inheritance or the possibility of systemic involve-
ment, although magnetic resonance angiography (MRA)
did rule out intracranial vascular involvement. Here, we
improve the clinical delineation of this syndrome by high-
lighting the following two additional features: (1) It is
autosomal-recessive in origin, and the mother-to-child
transmission in the original report was in fact a case of
pseudodominance, and (2) it is associated with supravalv-
ular pulmonic stenosis.
Despite the apparent lack of relatedness between the
eight study families and their different tribal and geo-
graphic backgrounds, our genetic analysis strongly sug-
gests that the disease mutation is of common ancestral
origin, and the very small shared haplotype makes it likely
that it is also ancient in origin.
The mutational mechanism of c.830-1G>A in FRAM is
not straightforward. One possibility is that the truncated
IGFBP7 (which we show to be stably produced) acts in
a dominant-negative manner. This is unlikely, however,
because IGFBP7 is not known to dimerize and because
heterozygous carriers are disease free. Similarly, the possi-
bility that this is a neomorphic mutation is unlikely given
the lack of manifestations in any of the many carriers we
evaluated clinically in the course of this study. Loss-of-
function is the mechanism we prefer not only because it
is the usual mutational mechanism in autosomal-recessive
diseases but also, and more importantly, because transcrip-
tomic analysis of lymphoblasts from FRAM patients
showed a pattern highly consistent with what is known
about IGFBP7 knockdown experiments, i.e., it showedThe American Journal of HumBRAF/MEK/ERK upregulation, which is
also supported by immunoblot analysis.
The observation that FRAM patients only
lack a small part of the C terminus of
IGFBP7 is intriguing because very little is
known about the functional importance
of the C terminus in IGFBPs other than
that it contains an immunoglobulin-like
domain.15 Thus, FRAM patients representa unique opportunity to observe the functional conse-
quences of the loss of that domain.
Before it was labeled as a gene encoding an insulin-like-
growth-factor-binding protein, IGFBP7 was originally
described as MAC25 (meningioma-associated cDNA), a
differentially expressed gene in meningioma and breast
cancer tissues, and the protein was identified as tumor-
derived cell adhesion factor (TAF), also called angiomodu-
lin.16,17 More recently, two major biological functions
have emerged for this protein. The first is related to its
tumor suppressor action, most notably in melanoma,
where it was shown tomediate BRAFV600E-induced senes-
cence by blocking the BRAF-MEK-ERK signaling.18–20 The
second is related to its ability to block VEGF-induced
angiogenesis in a manner that is not mediated via promo-
tion of apoptosis but rather via the blocking of VEGF-
induced activation of cyclooxygenase (COX)-2.21 How-
ever, despite these highly interesting biological actions of
IGFBP7, more comprehensive analysis has been limited
by a lack of an animal model until recently, when the
zebrafish ortholog was knocked down and the resulting
morphants displayed a remarkable defect of vascular
sprouting and patterning.15
FRAM, therefore, represents a unique opportunity to
observe the consequences of germline mutations in
IGFBP7 on vasculogenesis and angiogenesis. The highly
penetrant phenotype of supravalvular pulmonic stenosis
is consistent with the vascular patterning defect seen in
zebrafish.15 The upregulation of BRAF/MEK/ERK signaling
provides a tantalizing pathway on which both FRAMan Genetics 89, 313–319, August 12, 2011 317
and rasopathies—in particular cardiofaciocutaneous
syndrome, which is a RAS/MAPK disorder directly associ-
ated with activating mutations of BRAF and MEK1/2—
converge on the overlapping cardiac phenotype.22 More
interestingly, the highly unusual retinal vascular lesions
in FRAM represent an unexpected vascular defect in the
setting of defective IGFBP7. The observations that the
phenotype is probably not congenital, is progressive in
nature, and mostly affects larger branches of the retinal
arterial vasculature where the pressure is highest, make it
tempting to propose that the macroaneurysms in FRAM
are caused by reduced mechanical integrity of the arterial
vessel wall. The recent demonstration that IGFBP7 is
specifically expressed in the endothelium of smooth-
muscle-invested vasculature but not smaller capillaries is
consistent with our own findings and lends further sup-
port to our hypothesis.15 Lack of aneurysm in other
organs, such as the brain, that were screened in our study
is not necessarily in contradiction with the proposed
model because tissue-specific expression and redundancy
can be invoked as potential explanations. Indeed, IGFBP7
has an expression pattern that is largely restricted to the
eye and skeletal muscles in postnatal stages.15
In summary, we define FRAM as an autosomal-recessive
disorder characterized by progressive retinal artery macro-
aneurysms and suprvalvular pulmonic stenosis and caused
by biallelic mutation in IGFBP7. This report of a germline
mutation in an IGFBP in humans suggests a highly spe-
cific developmental role of IGFBP7 in the cardiovascular
system.Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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